Safety, Efficacy and Pharmacokinetics of ALD403

PHASE1CompletedINTERVENTIONAL
Enrollment

163

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

February 28, 2014

Conditions
Migraine
Interventions
BIOLOGICAL

ALD403

DRUG

Placebo

Trial Locations (26)

11235

SPRI, Brooklyn

14609

Rochester Clinical Research, Inc., Rochester

23454

Tidewater Integrated Medical Research, Virginia Beach

27612

Wake Research, Raleigh

29464

Coastal Carolina Research Center, Mt. Pleasant

33009

MD Clinical, Hallandale

33143

Miami Research, Miami

33161

Segal Institute for Clinical Research, North Miami

33409

Palm Beach Research Center, West Palm Beach

37421

ClinSearch, Chattanooga

45255

Community Research, Cincinnati

48104

Michigan Headache & Neurological Institute, Ann Arbor

65807

Clinvest, Springfield

76017

Neurology Associates of Arlington, Arlington

78705

Premiere Research, Austin

84106

CRI Lifetree, Salt Lake City

85027

Premiere Research, Phoenix

90404

CA Medical Clinic for Headache, Santa Monica

90806

Collaborative Neuroscience Network, Inc., Long Beach

92108

Medical Center for Clinical Research, San Diego

92801

ACT Trials, Anaheim

94109

San Francisco Clinical Research, San Francisco

94598

Diablo Clinical Research, Inc., Walnut Creek

98105

Seattle Women's: Health, Research, Gynecology, Seattle

02131

Boston Clinical Trials, Roslindale

02472

MedVadis Research, Watertown

Sponsors
All Listed Sponsors
lead

Alder Biopharmaceuticals, Inc.

INDUSTRY

NCT01772524 - Safety, Efficacy and Pharmacokinetics of ALD403 | Biotech Hunter | Biotech Hunter